Celldex drops in after-hours trading on phase 2 barzolvolimab results
Celldex stock drops after phase 2 barzolvolimab prurigo nodularis trial misses primary and secondary endpoints. Read more here.
YayaNews contributes financial news and market context through the YayaNews editorial workflow.
Celldex stock drops after phase 2 barzolvolimab prurigo nodularis trial misses primary and secondary endpoints. Read more here.
Celldex drops in after-hours trading on phase 2 barzolvolimab results | Seeking Alpha
Save
Play
(
<1min
)
Comments
Izzet Esmece/iStock via Getty Images
Celldex (
CLDX
) is down ~6% in after-hours trading Tuesday after phase 2 results for barzolvolimab for the chronic skin disease
prurigo nodularis missed primary and secondary goals.
The p
ercentage of patients with at least a 4-point improvement in WI-NRS, the
To ensure this doesnât happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please
report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.
Search field
Entering text into the input field will update the search result below
Entering text into the input field will update the search result below
Recommended For You
More
Trending News
See More
»
Original YayaNews editorial coverage, published for informational purposes.
This article is sourced from Seeking Alpha. It is for informational purposes only and does not constitute investment advice.
Topics & Symbols
Continue Reading
Related Reading
U.S. crude stockpiles rose 2.6M barrels last week, API says (USO:NYSEARCA)
American Petroleum Institute reportedly shows surprise build of 2.6M barrels of oil in US commercial stockpiles for the week ending July 17, breaking a streak of 13 straight weekly declines.
AAR Non-GAAP EPS of $1.53 beats by $0.15, revenue of $928M beats by $33.39M (NYSE:AIR)
AAR press release (AIR): Q4 Non-GAAP EPS of $1.53 beats by $0.15. Revenue of $928M (+23.0% Y/Y) beats by $33.39M. FIRST QUARTER AND FULL YEAR FY 2027 GUIDANCE T
OpenAI's Latest ChatGPT Project Targets Small Business Market, Adding a New Variable to US Tech Stocks
OpenAI launches a ChatGPT project tailored for small businesses, potentially reshaping the digital services landscape. This article analyzes its impact on US tech stocks, SaaS companies, and cloud giants, while exploring opportunities and challenges for small businesses.
Microsoft adds Grok plugin for Outlook (MSFT:NASDAQ)
Microsoft adds SpaceXAIâs Grok to Outlook, Excel, Word & PowerPointâget AI help drafting emails, searching web and managing inbox.
